Joint Formulary & PAD

Molnupiravir - Covid-19

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Red
Formulations :
  • Capsules
Associated Icons :
Restrictions / Comments :
Important

Primary care and outpatient prescribing of antivirals for COVID 19 treatment is through the CMDU service.

Hospital inpatients - as per local hospital guidelines

PAD Profile

ChemicalSubstance :
Molnupiravir
Indication :
Covid-19
Group Name :
Keywords :
Covid 19, Coronavirus, antivirals
Brand Names Include :
Lagevrio
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
3

Committee Recommendations (1)

The Surrey Heartlands Integrated Care System Area Prescribing Committee agreed that molnupiravir (Lagevrio) should be made available in line with NICE TA1056 for the treatment of COVID-19 for people who are at highest risk of becoming seriously ill as defined in section 5 of NICE's technology appraisal guidance on nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19 only if both nirmatrelvir plus ritonavir and sotrovimab are contraindicated or unsuitable.    

It is considered as a RED drug and should only be prescribed by individuals who have been assessed by the Covid Medicines Delivery Unit (or if a patient who falls into one of the highest-risk cohorts is in hospital and gets COVID-19 whilst an inpatient). Not for prescribing through A&E / hospital clinics.

Other Indications

Below are listed other indications that Molnupiravir is used to treat.

  • No records returned.